高级检索
当前位置: 首页 > 详情页

p53 Protects Cells from Death at the Heatstroke Threshold Temperature.

文献详情

资源类型:
Pubmed体系:
机构: [1]MOE Laboratory of Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou 310058, China [2]College of Animal Sciences, Zhejiang University, 866 Yu Hang Tang Road, Hangzhou 310058, China [3]Department of Plastic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun Road East, Hangzhou 310016, China [4]Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, 74 Second Zhonshan Road, Guangzhou 510080, China [5]Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA 02115, USA [6]Life Sciences Institute and Innovation Center for Signaling Network, Zhejiang University, 866 Yu Hang Tang Road, Hangzhou 310058, China [7]Center of Growth, Metabolism and Aging, College of Life Sciences, Sichuan University, Chengdu 610064, China
出处:

摘要:
When the core body temperature is higher than 40°C, life is threatened due to heatstroke. Tumor repressor p53 is required for heat-induced apoptosis at hyperthermia conditions (>41°C). However, its role in sub-heatstroke conditions (≤40°C) remains unclear. Here, we reveal that both zebrafish and human p53 promote survival at 40°C, the heatstroke threshold temperature, by preventing a hyperreactive heat shock response (HSR). At 40°C, both Hsf1 and Hsp90 are activated. Hsf1 upregulates the expression of Hsc70 to trigger Hsc70-mediated protein degradation, whereas Hsp90 stabilizes p53 to repress the expression of Hsf1 and Hsc70, which prevents excessive HSR to maintain cell homeostasis. Under hyperthermia conditions, ATM is activated to phosphorylate p53 at S37, which increases BAX expression to induce apoptosis. Furthermore, growth of p53-deficient tumor xenografts, but not that of their p53+/+ counterparts, was inhibited by 40°C treatment. Our findings may provide a strategy for individualized therapy for p53-deficient cancers. Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 生物学
小类 | 2 区 细胞生物学
最新[2023]版:
大类 | 1 区 生物学
小类 | 2 区 细胞生物学
第一作者:
第一作者机构: [1]MOE Laboratory of Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou 310058, China [5]Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA 02115, USA
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43390 今日访问量:1 总访问量:3121 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号